Condition
Lichen Sclerosus of Vulva
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting1
Withdrawn1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05953090Not ApplicableRecruiting
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT07260825Phase 2Not Yet Recruiting
Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial
NCT05364515Phase 3WithdrawnPrimary
Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva
NCT03045172Not ApplicableCompletedPrimary
Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus
Showing all 4 trials